Fundamental Analysis of ADAPTIMMUNE THERAPEUTICS-ADR(NASDAQ:ADAP) stock

Fundamental Rating

ADAP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While ADAP seems to be doing ok healthwise, there are quite some concerns on its profitability. ADAP is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ADAP has reported negative net income.

ADAP had a negative operating cash flow in the past year.

ADAP had negative earnings in each of the past 5 years.

In the past 5 years ADAP reported 4 times negative operating cash flow.

1.2 Ratios

With a decent Return On Assets value of -40.29%, ADAP is doing good in the industry, outperforming 60.58% of the companies in the same industry.

With a Return On Equity value of -288.18%, ADAP is not doing good in the industry: 73.72% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-40.29%
ROE	-288.18%
ROIC	N/A

ROA(3y)-41.42%

ROA(5y)-45.74%

ROE(3y)-188.98%

ROE(5y)-143.21%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ADAP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADAP does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ADAP has more shares outstanding

Compared to 5 years ago, ADAP has more shares outstanding

There is no outstanding debt for ADAP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ADAP has an Altman-Z score of -5.13. This is a bad value and indicates that ADAP is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of ADAP (-5.13) is worse than 63.31% of its industry peers.

There is no outstanding debt for ADAP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.13

ROIC/WACCN/A

WACC8.67%

2.3 Liquidity

A Current Ratio of 2.85 indicates that ADAP has no problem at all paying its short term obligations.

ADAP has a worse Current ratio (2.85) than 68.43% of its industry peers.

ADAP has a Quick Ratio of 2.85. This indicates that ADAP is financially healthy and has no problem in meeting its short term obligations.

ADAP has a worse Quick ratio (2.85) than 66.72% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.85
Quick Ratio	2.85

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.60% over the past year.

ADAP shows a strong growth in Revenue. In the last year, the Revenue has grown by 121.95%.

Measured over the past years, ADAP shows a small growth in Revenue. The Revenue has been growing by 0.26% on average per year.

EPS 1Y (TTM)33.6%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-33.33%

Revenue 1Y (TTM)121.95%

Revenue growth 3Y147.83%

Revenue growth 5Y0.26%

Revenue growth Q2Q-97.91%

3.2 Future

The Earnings Per Share is expected to grow by 1.81% on average over the next years.

ADAP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.34% yearly.

EPS Next Y58.06%

EPS Next 2Y19.65%

EPS Next 3Y9.91%

EPS Next 5Y1.81%

Revenue Next Year-13.04%

Revenue Next 2Y-10.88%

Revenue Next 3Y-13.18%

Revenue Next 5Y11.34%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ADAP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAP. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.65%

EPS Next 3Y9.91%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ADAP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (5/2/2024, 4:20:00 PM)

1.19

-0.02 (-1.65%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap304.12M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-40.29%
ROE	-288.18%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.85
Quick Ratio	2.85
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)33.6%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y58.06%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)121.95%

Revenue growth 3Y147.83%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ADAPTIMMUNE THERAPEUTICS-ADR (ADAP)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens